Answers are grounded in this paper and cite their sources.
BACKGROUND Chiari malformation type I (CM-I) is characterized by cerebellar tonsil position ≥ 5 mm below the foramen magnum, which can disrupt CSF flow and lead to syringomyelia. Pro-inflammatory processes have been associated with heightened CNS inflammation and altered CSF dynamics, mechanisms that may contribute to CM-I and syringomyelia pathogenesis, although the precise relationship remains uncertain. Anti-inflammatory interventions, including dietary modification and pharmacological therapies such as metformin, may offer neuroprotective benefits by mitigating neuroinflammation and improving neurological outcomes. OBSERVATIONS The authors describe the cases of 2 pediatric patients with CM-I and syringomyelia who demonstrated clinical and radiographic improvement following anti-inflammatory interventions. Both patients initially presented with symptomatic CM-I, cerebellar tonsil position > 5 mm below the foramen magnum, and syringomyelia. A 7-year-old female was started on a diet intended to reduce inflammation and restrict gluten and sugar and subsequently demonstrated stable tonsil position, reduced syrinx size, and symptomatic improvement of hand paresthesias. A 9-year-old female began metformin therapy and experienced stable tonsil position, reduction in a multiloculated syrinx, and resolution of symptoms. LESSONS These cases suggest that anti-inflammatory interventions may contribute to symptom improvement and syrinx reduction in CM-I–associated syringomyelia, supporting further investigation into inflammation as a therapeutic target in CM-I pathogenesis. https://thejns.org/doi/10.3171/CASE26496
No takes yet. Share an insight, caveat, or question.
Landwehr et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: